J&J's boost in Doxil supply benefits study of Endocyte/Merck drug

Johnson & Johnson ($JNJ) has come through with more of its cancer drug Doxil to fill orders from biotechs that need the drug for their clinical trials, after months of rationing the drug because of a key supplier's manufacturing problems. As The Wall Street Journal reported, Endocyte ($ECYT) is grabbing some of the extra Doxil for a late-stage trial of its drug partnered with Merck ($MRK) for ovarian cancer. Endocyte is testing a combination of its experimental EC145 in combination with Doxil versus Doxil alone. Article

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.